198 related articles for article (PubMed ID: 22568622)
1. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
Marín F; Roldán V; Lip GY
Expert Opin Pharmacother; 2012 Jun; 13(8):1087-90. PubMed ID: 22568622
[No Abstract] [Full Text] [Related]
2. Australian MPs demand more data on dabigatran for atrial fibrillation.
Brill D
BMJ; 2013 Jan; 346():f303. PubMed ID: 23321733
[No Abstract] [Full Text] [Related]
3. Stroke prevention in atrial fibrillation.
Wagenaar P
Cardiovasc J Afr; 2011; 22(2):105. PubMed ID: 21556458
[No Abstract] [Full Text] [Related]
4. Benefits of dabigatran maintained for more than two years.
Aalbers J
Cardiovasc J Afr; 2012 Nov; 23(10):576. PubMed ID: 23192264
[No Abstract] [Full Text] [Related]
5. [Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
Zotova IV; Zateĭshchikov DA
Kardiologiia; 2014; 54(2):79-85. PubMed ID: 24888206
[No Abstract] [Full Text] [Related]
6. [Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
Calvo Romero JM
Rev Clin Esp; 2011 Mar; 211(3):142-6. PubMed ID: 21371701
[TBL] [Abstract][Full Text] [Related]
7. Public health. Change of heart.
Taylor J
Health Serv J; 2012 Jul; 122(6315):19-20. PubMed ID: 23155563
[No Abstract] [Full Text] [Related]
8. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
Fieland D; Taylor M
Ann Pharmacother; 2012 Jan; 46(1):e3. PubMed ID: 22202498
[TBL] [Abstract][Full Text] [Related]
9. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Morales-Vidal S; Schneck MJ; Flaster M; Biller J
Expert Rev Neurother; 2012 Feb; 12(2):179-89; quiz 190. PubMed ID: 22288673
[TBL] [Abstract][Full Text] [Related]
10. Update on dabigatran for stroke prevention in atrial fibrillation.
Henry DM
Conn Med; 2011 Sep; 75(8):479-83. PubMed ID: 21980679
[No Abstract] [Full Text] [Related]
11. [Direct oral thrombin inhibitor, "dabigatran"].
Yasaka M
Nihon Rinsho; 2013 Jan; 71(1):113-8. PubMed ID: 23631181
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.
Mack DR; Kim JJ
Ann Pharmacother; 2012; 46(7-8):1105-10. PubMed ID: 22764329
[TBL] [Abstract][Full Text] [Related]
13. Stroke risk reduction: focus of the new ESC guidelines.
Aalbers J
Cardiovasc J Afr; 2011; 22(2):106. PubMed ID: 21556459
[No Abstract] [Full Text] [Related]
14. [Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: complex clinical situations and real clinical practice].
Tkacheva ON; Akasheva DU
Ter Arkh; 2014; 86(4):103-7. PubMed ID: 24864477
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran for stroke prevention in all patients with atrial fibrillation?
Hunchuck JE; Lake JD
Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
[No Abstract] [Full Text] [Related]
16. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Barrios V; Escobar C
Expert Opin Pharmacother; 2012 Dec; 13(18):2649-61. PubMed ID: 23167273
[TBL] [Abstract][Full Text] [Related]
17. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Connolly SJ; Wallentin L; Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Pogue J; Alings M; Amerena JV; Avezum A; Baumgartner I; Budaj AJ; Chen JH; Dans AL; Darius H; Di Pasquale G; Ferreira J; Flaker GC; Flather MD; Franzosi MG; Golitsyn SP; Halon DA; Heidbuchel H; Hohnloser SH; Huber K; Jansky P; Kamensky G; Keltai M; Kim SS; Lau CP; Le Heuzey JY; Lewis BS; Liu L; Nanas J; Omar R; Pais P; Pedersen KE; Piegas LS; Raev D; Smith PJ; Talajic M; Tan RS; Tanomsup S; Toivonen L; Vinereanu D; Xavier D; Zhu J; Wang SQ; Duffy CO; Themeles E; Yusuf S
Circulation; 2013 Jul; 128(3):237-43. PubMed ID: 23770747
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
Messori A; Fadda V; Maratea D; Trippoli S
J Cardiovasc Med (Hagerstown); 2013 Sep; 14(9):683-5. PubMed ID: 23032961
[No Abstract] [Full Text] [Related]
19. [Advantages of NOAKs validated in clinical routine].
Ameri AA
MMW Fortschr Med; 2015 May; 157(9):70. PubMed ID: 26012835
[No Abstract] [Full Text] [Related]
20. [Waiting for the new oral anticoagulants: questions and answers about dabigatran].
Verdecchia P; Agnelli G
G Ital Cardiol (Rome); 2013 Jan; 14(1):35-45. PubMed ID: 23258203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
